Lipase Elevation in Patients With COVID-19
- 1 August 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in The American Journal of Gastroenterology
- Vol. 115 (8), 1286-1288
- https://doi.org/10.14309/ajg.0000000000000732
Abstract
INTRODUCTION: Although coronavirus disease (COVID-19) has been associated with gastrointestinal manifestations, its effect on the pancreas remains unclear. We aimed to assess the frequency and characteristics of hyperlipasemia in patients with COVID-19. METHODS: A retrospective cohort study of hospitalized patients across 6 US centers with COVID-19. RESULTS: Of 71 patients, 9 (12.1%) developed hyperlipasemia, with 2 (2.8%) greater than 3 times upper limit of normal. No patient developed acute pancreatitis. Hyperlipasemia was not associated with poor outcomes or symptoms. DISCUSSION: Although a mild elevation in serum lipase was observed in some patients with COVID-19, clinical acute pancreatitis was not seen.This publication has 6 references indexed in Scilit:
- Pancreatic Injury Patterns in Patients With Coronavirus Disease 19 PneumoniaGastroenterology, 2020
- Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive studyThe Lancet, 2020
- Tu1424 – Marked Serum Lipase Elevations are Associated with Longer Hospitalizations in Patients with Non-Pancreatic HyperlipasemiaGastroenterology, 2019
- Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensusGut, 2012
- Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesisThe Journal of Pathology, 2004